CannTrust Suspends All Medical Sales Pending Health Canada Investigation
The scandal surrounding CannTrust’s non-compliance due to five unlicensed grow rooms has been a topic of interest for the past few days. But based on an update by Global News and a direct message to clients, things are as bad as they can get.
Initially, news developments implied that, despite a substantial amount of product being mandatorily or voluntarily held, sales would continue for any remaining stock.
However, a recent e-mail to CannTrust’s medical clients showed that this is not the case. Naturally, this is disappointing and distressing to the over 70,000 medical clients CannTrust serves – the author of this article being one of them.
Unfortunately, this leaves everyone with a slew of questions and few answers – the most important being when new product will be available.
Late in the evening on July 11th, CannTrust’s clients received an e-mail about the situation. One excerpt reads as follows:
“Dear CannTrust Patient,
We deeply value the trust you place in us to provide you with your medical cannabis products. We are currently working on a facility review with Health Canada and as a precaution, we have implemented a voluntary hold on the sale of our medical products as of July 10th, 2019.”
Because the infraction occurred at their lone harvesting facility in Pelham, Ontario (manufacturing is done in Vaughn), their entire supply is in question. According to the rest of their message, they halted sales in the interest of consumer safety:
“Your safety is our first priority and we would like to assure you that all previously sold and current inventory products have passed quality control testing at Health Canada approved labs as well as CannTrust’s own quality control processes and safety reviews.
We thank you for your patience and sincerely apologize for the inconvenience this may cause. We are working diligently to correct the matter and will keep you informed.”
At least customers can feel safe knowing that they did not purchase any contaminated or substandard products.
However, this leaves over 70,000 patients with a choice. They can either switch providers or wait out the storm. But given how long government investigations can take, it is likely that this storm will be a long one.
Naturally, this author sent an e-mail to CannTrust’s customer service in hopes of getting answers about the shortage. Unsurprisingly, it failed to shed any light on the situation.
When asked if they had a rough idea as to when supply would be available, their response was:
“Thank you for your email. Ensuring product safety and availability is our priority but at this time, we do not have a definitive answer.”
This does not mean that CannTrust is simply going to wait, however. The reply continues:
“We are exploring options to mitigate product shortages and will keep you informed as soon as product becomes available.”
Global News offers a similar answer. Based on a press release earlier during the day on July 11th, the company said:
“CannTrust is working closely with the regulator through the review process and expects to provide further detail of the duration of the hold and other development as they become available.”
Perhaps the one redeeming quality in this entire situation is CannTrust’s transparency.
WeedAdvisor’s Commitment to Quality and Safety
At this point, it little else can be said about the situation with CannTrust. Until Health Canada and CannTrust are done with the appropriate procedures (and consequences), CannTrust is essentially in limbo. This will likely have a catastrophic financial impact on the company. Fortunately, clients have plenty of great options to choose from.
To make the choice easier, WeedAdvisor has so far provided product descriptions for the vast majority of Canadian licensed producers, available in our “Reviews” section.